Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer

  • Junyong OU ,
  • Kunming NI ,
  • Lulin MA ,
  • Guoliang WANG ,
  • Ye YAN ,
  • Bin YANG ,
  • Gengwu LI ,
  • Haodong SONG ,
  • Min LU ,
  • Jianfei YE ,
  • Shudong ZHANG
Expand
  • 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Pathology, Peking University Third Hospital, Beijing 100191, China

Received date: 2024-03-18

  Online published: 2024-07-23

Abstract

Objective: To investigate the prognostic factors for all-cause mortality in patients with muscle-invasive bladder cancer (MIBC) with intermediate-to-high-risk primary prostate cancer. Methods: From January 2012 to October 2023, the clinical data of the patients with MIBC with intermediate-to-high-risk primary prostate cancer in Peking University Third Hospital were retrospectively analyzed. All the patients were monitored and the occurrence of all-cause death was documented as the outcome event in the prognostic study. Univariate and multivariate Cox proportional risk regression analysis models were implemented to search for independent influences on the prognosis of patients. For significant influencing factors (pathological T stage, M stage and perineural invasion of bladder cancer), survival curves were plotted before and after multifactorial Cox regression adjusting for confounding factors. Results: A total of 32 patients were included in this study. The mean age was (72.5±6.6) years; the median preoperative total prostate specific antigen (tPSA) was 6.68 (2.47, 6.84) μg/L; the mean preoperative creatinine was (95±36) μmol/L, and the median survival time was 65 months. The majority of the patients (87.5%) had high-grade bladder cancer, 53.1% had lymphatic invasion, and 31.3% had perineural invasion. Prostate involvement was observed in 25.0% of the cases, and the positive rate of soft-tissue surgical margin was 37.5%. Multivariate Cox analysis revealed that preoperative creatinine level (HR=1.02, 95%CI: 1.01-1.04), pathological stage of bladder cancer T3 (HR=11.58, 95%CI: 1.38-97.36) and T4 (HR=19.53, 95%CI: 4.26-89.52) metastasis of bladder cancer (HR=9.44, 95%CI: 1.26-70.49) and perineural invasion of bladder cancer (HR=6.26, 95%CI: 1.39-28.27) were independent prognostic factors (P < 0.05). Survival curves with Log-rank test after adjusting for confounding factors demonstrated that bladder cancer pathology T3, T4, M1, and perineural invasion were unfavorable factors affecting the patients' survival prognosis (P < 0.05). Conclusion: Patients with MIBC with intermediate-to-high risk primary prostate cancer generally portends a poor prognosis. High preoperative serum creatinine, T3 or T4 pathological stage of bladder cancer, metastasis of bladder cancer and bladder cancer perineural invasion are poor prognostic factors for patients with MIBC with intermediate-to-high risk primary prostate cancer.

Cite this article

Junyong OU , Kunming NI , Lulin MA , Guoliang WANG , Ye YAN , Bin YANG , Gengwu LI , Haodong SONG , Min LU , Jianfei YE , Shudong ZHANG . Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer[J]. Journal of Peking University(Health Sciences), 2024 , 56(4) : 582 -588 . DOI: 10.19723/j.issn.1671-167X.2024.04.006

References

1 Alfred Witjes J , Max Bruins H , Carrión A , et al. European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines[J]. Eur Urol, 2024, 85 (1): 17- 31.
2 Siegel RL , Giaquinto AN , Jemal A . Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74 (1): 12- 49.
3 Dyrskj?t L , Hansel DE , Efstathiou JA , et al. Bladder cancer[J]. Nat Rev Dis Primers, 2023, 9 (1): 58.
4 Compérat E , Amin MB , Cathomas R , et al. Current best practice for bladder cancer: A narrative review of diagnostics and treatments[J]. Lancet, 2022, 400 (10364): 1712- 1721.
5 Lopez-Beltran A , Cheng L , Montorsi F , et al. Concomitant bladder cancer and prostate cancer: Challenges and controversies[J]. Nat Rev Urol, 2017, 14 (10): 620- 629.
6 Jing Y , Zhang R , Ma P , et al. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate[J]. J Pathol, 2018, 244 (1): 5- 10.
7 Aljabery F , Liedberg F , H?ggstr?m C , et al. Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: A nationwide population-based study in the bladder can-cer data base Sweden (BladderBaSe)[J]. BJU Int, 2020, 126 (5): 625- 632.
8 Claps F , Pavan N , Umari P , et al. Incidence, predictive factors and survival outcomes of incidental prostate cancer in patients who underwent radical cystectomy for bladder cancer[J]. Minerva Urol Nephrol, 2021, 73 (3): 349- 356.
9 Malte R , Kluth LA , Kaushik D , et al. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study[J]. Eur J Surg Oncol, 2017, 43 (11): 2193- 2199.
10 Fahmy O , Khairul-Asri MG , Schubert T , et al. Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: A systematic review and meta-analysis of 13 140 patients[J]. J Urol, 2017, 197 (2): 385- 390.
11 Kaelberer JB , O'donnell MA , Mitchell DL , et al. Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: Disease-specific outcomes and survival[J]. Prostate Int, 2016, 4 (3): 107- 112.
12 Wu S , Lin SX , Lu M , et al. Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy[J]. Int Urol Nephrol, 2019, 51 (9): 1527- 1535.
13 Mazzucchelli R , Barbisan F , Scarpelli M , et al. Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?[J]. Am J Clin Pathol, 2009, 131 (2): 279- 283.
14 Moschini M , Shariat SF , Freschi M , et al. Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer[J]. Urol Int, 2017, 98 (3): 290- 297.
Outlines

/